To receive coverage for Xarelto, a person must be enrolled in a Medicare Part D prescription drug plan or a Medicare Advantage (Part C) plan that includes prescription drug coverage. This article ...

Janssen, a subsidiary of Johnson & JohnsonJNJ, announced that the FDA has approved the label expansion of its blood thinner, Xarelto. The drug is now approved for reduction in risk of major ...

The FDA approved the anticoagulant rivaroxaban (Xarelto, Janssen), to reduce the risk for stroke among patients with non-valvular atrial fibrillation (AF). Approval comes after data from the ROCKET-AF ...

Bayer AGBAYRY and partner J&J JNJ announced data from two late-stage studies, which showed that its blood thinner drug, Xarelto failed to show statistical benefits. These studies were being evaluated ...

The oral blood thinner Xarelto (rivaroxaban) significantly reduced blood clots for high-risk patients with cancer being treated in the outpatient setting, according to results from the CASSINI trial.